Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

act is significantly reduced and, as the iron is retained within the product if it is not absorbed, it is expected this will significantly reduce the risk of unwanted side effects within the gastrointestinal tract.

The international, multicentre, randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 studies will investigate the potential of ST10 as a twice-daily treatment of IDA in subjects with Ulcerative Colitis (UC) or Crohn's disease respectively where oral ferrous preparations have failed or cannot be used.  The studies are each enrolling 120 patients and will measure patients' change in haemoglobin concentration from baseline to week 12.  Initial results from both studies are expected to be reported in late 2012 and, if positive, will be promptly followed by filings of marketing authorisation applications in key pharmaceutical markets.  In addition, Shield is planning to initiate a Phase 3 study of ST10 for the treatment of IDA in patients with chronic kidney disease in 2012.  

Data provided by IMS suggests that the iron market was worth $2.4 billion in 2010, of which 55% of revenues were generated from oral iron therapies.

There are currently no curative treatments available for UC or Crohn's and so treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse.  IDA in both is a chronically debilitating disorder which has a significant impact on patients' quality of life and, as a result, its treatment is an important aspect of disease management.  Characteristic symptoms of IDA include chronic fatigue, headache and subtle impairment of cognitive function.  Up to one third of subjects with UC and Crohn's suffer from recurrent anaemia, with hospitalisation required in severe cases.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an ind
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... As a symbol of its commitment ... pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to announce ... Race Team for the 2015 race season. Success on ... a strong sense of precision and attention to detail. ... in the quality control testing laboratory. Sponsorship of the ...
(Date:3/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... prearranged trading plan in accordance with Securities and Exchange ... CEO of Neogen Corporation, is a minority owner of ... stock. Herbert does not have control of ... filing is only for a portion of the shares ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
Breaking Biology Technology:Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Neogen CEO adopts 10b5-1 Trading Plan 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... Replikins Ltd. published a FluForecast(R) warning in April 7th, ... H1N1 cases. The company was able to state the ... Count(TM) genomics technology, which examines specific regions in virus ... 2008 announcement, attached below as published on the Web, ...
... cells to combat aging and help support healing , ... ... Aesthetics , a division of Histogen focused on providing unique, clinically ... launch of the ReGenica™ Rejuvenation System for anti-aging and post-resurfacing. ...
... Mass., April 27 LaVoie Group, a life science-focused ... selected as investor relations agency of record for Pegasus ... LaVoie Group, commented, "Pegasus has the opportunity to capture ... The Company is changing the standard of care in ...
Cached Biology Technology:Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 2Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 3Histogen Aesthetics Launches ReGenica Rejuvenation System 2Histogen Aesthetics Launches ReGenica Rejuvenation System 3Histogen Aesthetics Launches ReGenica Rejuvenation System 4LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster 2
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... burn crop residues and get the land ready for ... image from the MODIS instrument on the Aqua satellite. ... fires can be found at this URL: http://www.nasa.gov/mission_pages/fires/main/world/20130326-indochina.html ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua ...
... genes to living human tissue, the odds of success come ... used to bring new genetic material into a cell ... process will simplify non-viral transfection, providing a method researchers and ... deliver genes to cells. Developed by William Murphy, ...
... led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular ... first to report that two specific tumor suppressor genes work ... tumor cells to the lungs. The research is published this ... Working in a mouse model, the LSUHSC research team studied ...
Cached Biology News:Material screening method allows more precise control over stem cells 2LSUHSC research discovers new drug target for metastatic breast cancer 2
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: